Menu
GrowthWorks Canadian Fund
Transaction Overview
Rosetta Capital completed a secondary transaction to acquire a portfolio of eight life sciences assets from GrowthWorks, a Canadian fund manager.
Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience.
Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience.
Supporting portfolio companies for the next growth phase
Rosetta Capital supported the portfolio companies acquired in the transaction through the growth phase and made several follow-on investments.
Rosetta partners joined the boards of acquired portfolio companies and were actively involved in strategic decision making, leading to multiple exits.
Rosetta partners joined the boards of acquired portfolio companies and were actively involved in strategic decision making, leading to multiple exits.
